OsteoSys has been providing clinical body composition analyzers for over 20 years, with around 20,000 systems installed worldwide and 80% market share in its home country, South Korea. With a strong background in R&D, OsteoSys took its experience with clinical DXA technology and brought iNSiGHT to preclinical research market.
iNSiGHT is a fully shielded DXA (dual energy x-ray absorptiometry) system, designed specifically for use on preclinical small animal models such as mice and rats. The technology provides quantification of body composition, such as bone mineral density (BMD), bone mineral content (BMC), and measures of lean and fat mass.
Study body composition non-invasively, with low dose radiation, and superfast scan time (25s.) suitable for longitudinal studies on the same animals.